

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office, on the date shown below.

Dated: November 27, 2007 Signature: /Mark D. Russett/
Mark D. Russett, Reg. No. 41,281

Docket No.: 62936 (46342)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Takafumi Ishii et al.

Application No.: 10/525,105

Confirmation No.: 2820

Filed: February 18, 2005

Art Unit: 1642

For: PREVENTIVES/REMEDIES FOR CANCER

Examiner: L. Yao

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants are in receipt of the Office Communication dated October 4, 2007, and now submit this response. A request for an extension of time accompanies this paper, which is therefore believed to be timely.

Applicants respectfully request reconsideration of the Restriction Requirement on the grounds that examination of the groups specified in the Restriction should not impose an undue burden. Additionally, significant expense and time would be saved if all of the groups (i.e., all pending claims) were searched and examined at this time.

However, solely to comply with the Restriction Requirement, Applicants select with traverse the invention of Group 2, claims 4-10, 12, 13, 17-18, 25, 28-29, and 43, drawn to a polynucleotide, antisense polynucleotide that is complementary to the polynucleotide, vector, transformant, pharmaceutical composition, diagnostic agent, or kit comprising the polynucleotide as set forth in the Office Communication.

Moreover, solely to comply with the requirement that Applicants select a single disclosed species, Applicants elect the sequence of SEQ ID NO: 16.

It is believed that, of the selected claims, at least claims 4-10, 12, 13, 17-18, 25, and 43 read upon the elected species.

The election of Group 2 and the above election of species are made to comply with the Restriction Requirement, without prejudice, and the right to file divisional applications on non-elected subject matter is reserved.

The Examiner has indicated that withdrawn process claims containing all the limitations of an allowable product claim will be rejoined pursuant to MPEP 821.04. Applicants further respectfully request that rejoinder of all groups be considered by the Examiner.

Early and favorable consideration of the application is earnestly solicited.

Applicants conditionally petition for any further extension of time required. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 62936 (46342).

Dated: November 27, 2007

Respectfully submitted,

By /Mark D. Russett/ .

Mark D. Russett, Registration No.: 41,281

EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 239-0100

Attorneys/Agents For Applicants